TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03357029

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GammaCore Device
Description: GammaCore will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Sham device will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes. The sham device is identical in appearance, weight, visual and audible feedback, and user application and control but did not deliver electrical stimulations.
Study: NCT03790813

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: Ki-67 and Oncotype DX® will be performed on the baseline core biopsy specimen prior to initiation of neoadjuvant systemic therapy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: MRI will be performed prior to initiation of neoadjuvant systemic therapy and at the end of treatment.
Study: NCT04431843

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina maxima extract
Description: once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 1.5 g/day) for 12 week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 0 g/day) for 12 week
Study: NCT02365610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42006

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Study: NCT04220320

Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal examination.
Description: Cervical properties as evaluated by a vaginal examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal examination.
Description: Cervical properties as evaluated by a vaginal examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal sonography.
Description: Cervical length as evaluated by a transvaginal sonography.
Study: NCT00523562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet intervention
Description: controlled hypercaloric high fructose, high fat, or high fat/high protein diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet intervention
Description: controlled hypercaloric high fructose, high fat, or high fat/high protein diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet intervention
Description: controlled hypercaloric high fructose, high fat, or high fat/high protein diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet intervention
Description: controlled hypercaloric high fructose, high fat, or high fat/high protein diet
Study: NCT04639375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinated with polio vaccine (IPV)
Description: poliovirus vaccine (IPV) manufactured by Sanofi Pasteur for distribution in the United States
Study: NCT03118635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Physical activity programming in accordance with the SPARK - After School curriculum as well as engaging activities provided by local community partners. The intervention proceeded the SFSP lunch meal service, so that children received approximately three hours of physical activity programming daily.
Study: NCT00972868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)
Description: The regular face mask will be replaced with the study mask and patients will receive NPPV via the study mask for 30 min. The study mask insures a unidirectional breathing pattern, in through the nose and out through the mouth or in through the mouth and out through the nose. The sequence of these two breathing patterns with opposite flow direction will be chosen randomly. Each will be applied for 30 min with data collected during and at the end of the period.
Study: NCT02470585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Capsules for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).
Study: NCT01776112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
Study: NCT02318069

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FSME-immune
Description: 0.5 ml im as scheduled in the 5 arms

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FSME-immune
Description: 0.5 ml im as scheduled in the 5 arms

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FSME-immune
Description: 0.5 ml im as scheduled in the 5 arms
Study: NCT02033850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Process Training-II
Description: Rehabilitation of attention using the Attention Process Training-II
Study: NCT02470585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Veliparib
Description: Capsules for oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to Veliparib
Description: Capsules for oral administration
Study: NCT03221465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring of physical activity with incentives
Description: Participants are given a pedometer (e.g. Misfit brand wrist pedometer) to allow self-monitoring of physical activity and receive financial incentives. Participants also answer two health questions a week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care and self-monitoring of physical activity
Description: Participants simply given a pedometer (e.g. Misfit brand wrist pedometer) with no other intervention to allow self-monitoring of physical activity.
Study: NCT02991898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of Treg
Description: Allopurinol on day -7 to day 0 Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2 Total Body Irradiation 200 cGy as a single dose~Sirolimus 8mg-12mg oral loading dose followed by single dose 4mg/day. Levels are to be monitored 3 times/week in the first week, weekly until day +60, and as clinically indicated until day +100 post-transplantation.~Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses. Stop MMF at day +30 or 7 days after neutrophil recovery, whichever day is later, if no acute GVHD.~DUCBT followed Tregs - double umbilical cord blood transplant (FIRST) followed by the Treg cell infusion (SECOND) no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion.
Study: NCT03263988

Intervention type: DEVICE
Intervention: ConCardiac
Description: All patients receive a piezocapacitative-interlayer-technology hemodynamic measurement by ConCardiac device (SectorCon GmbH, Berlin, Germany).
Study: NCT01551654

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (ITO Company )
Description: A mobile small machine for nerve stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (ITO Company )
Description: A mobile small machine for nerve stimulation
Study: NCT03267979

Intervention type: OTHER
Group type: OTHER
Intervention: Video-pupillometer
Description: Video-pupillometer will be performed. In this study data will be collected and analyzed.

Intervention type: OTHER
Group type: OTHER
Intervention: Electrocardiogram
Description: Electrocardiogram will be performed. In this study data will be collected and analyzed.
Study: NCT03548896

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post extraction socket
Description: \*\*Dental implant will be placed 3 months after tooth extraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post extraction socket
Description: \*\*Dental implant will be placed 3 months after tooth extraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post extraction socket
Description: \*\*Dental implant will be placed 3 months after tooth extraction
Study: NCT00819156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: Degarelix was given as subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: Degarelix was given as subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: Degarelix was given as subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: Degarelix was given as subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: Degarelix was given as subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: Degarelix was given as subcutaneous injections.
Study: NCT01162252

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction
Description: The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living Well
Description: The Living Well (LW) program involves a series of informational presentations and group discussions on a variety of topics related to the promotion of health and well-being. The 8-week program is designed to provide participants with knowledge about ways to improve their physical and emotional health as a complement to traditional medical treatments.
Study: NCT04224103

Intervention type: DRUG
Intervention: Inhaled nitric oxide
Description: Stage 1: Patients in whom VA ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration, and thirty minutes after initiation. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be weaned. All parameters will be re-evaluated 30 minutes after iNO discontinuation.~Stage 2: iNO will be re-initiated 30 minutes prior to the ECMO weaning trial. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA ECMO and 30 minutes thereafter. If successful, data will be collected after the wean and after iNO discontinuation.
Study: NCT01776112

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TableSoccer
Description: Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
Study: NCT01155271

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: 12 weeks : 3 sessions per week (2 supervised sessions and 1 session at home)~1 technical visit and 1 nursing visit every two months at home for the CPAP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: 12 weeks : 3 sessions per week (2 supervised sessions and 1 session at home)~1 technical visit and 1 nursing visit every two months at home for the CPAP
Study: NCT01281865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study: NCT00585143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335
Description: 45 mg once daily for 10 consecutive days
Study: NCT03873298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: Inhaled nitric oxide delivered through a pulsatile nitric oxide drug delivery system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: Inhaled nitric oxide delivered through a pulsatile nitric oxide drug delivery system
Study: NCT02949050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: subcutaneous allergen immunotherapy (SCIT)
Description: 20 patients who (prior to study enrollment and initiation) completed more than 1 year of timothy grass SCIT vs. 20 control patients who underwent corn pollen exposure for for greater than one year during the same prestudy time interval. Efficacy will be assessed by analyses of symptom score surveys and quality of life surveys.
Study: NCT00585143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg once daily for 10 days
Study: NCT02508181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: supraglottic airway device without cuff

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme
Description: supraglottic airway device with cuff
Study: NCT02949050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCIT
Description: Treatment group consists of patients who completed \> 1 year of SCIT while control group patients did not undergo SCIT
Study: NCT01480583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRN1005
Description: 550 mg/m2 IV every 3 weeks
Study: NCT02295384

Intervention type: OTHER
Intervention: Retrospective Audit
Description: Retrospective Audit
Study: NCT01480583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRN1005
Description: 550 mg/m2 IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 2 mg/kg IV every week or 6 mg/kg IV every 3 weeks per investigator choice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FLT
Description: 5 mCi of 18F-FLT IV during Screening and during Cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FLT
Description: 5 mCi of 18F-FLT IV during Screening and during Cycle 1
Study: NCT01218373

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HOMESWEETHOME Services
Description: Monitoring and alarm handling services. eInclusion services. Domotic services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No HOMESWEETHOME services installed
Description: Normal care and healthcare without HOMESWEETHOME services.
Study: NCT01147159

Intervention type: OTHER
Group type: OTHER
Intervention: Extracts of allergens
Description: Skin prick test of extracts of allergens in 4 tenfold dilutions. Assessment wheal size after 15 minutes
Study: NCT03144128

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 5,000IU vitamin D given daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules given daily for 12 weeks
Study: NCT02434549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dysport®
Description: Intramuscular injections in spastic muscle with regional muscle-related pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intramuscular injections in spastic muscle with regional muscle-related pain
Study: NCT01130909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.5 mg/kg
Study: NCT02621060

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 1200 mg per day for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorogenic acid
Description: Chologenic acid: 1200 mg per day for three months
Study: NCT00573612

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Counseling
Description: Subjects will receive educational-based telephone counseling regarding fibromyalgia.
Study: NCT01130909

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 125 mL sterile NaCl 0.9%
Study: NCT01800331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text2bHealthy
Description: The intervention group uses handheld computers to keep track of their lifestyle behaviours and they will receive feedback on thier progress and tips (Text2bHealthy)
Study: NCT02689414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Description: Ischaemia is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 200 mm Hg or to a value that is 20 mm Hg greater than the patient's systolic blood pressure - if the patient's systolic blood pressure is more than 180 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control to RIPC
Description: Venous pressure is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 10-20 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
Study: NCT01127672

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: 30 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP).~Under sterile conditions, patients will receive a 3 cc PRP injection (consisting of their own PRP) with 1 cc of 2% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid injection
Description: Under sterile conditions, patients will receive a 4 cc injection consisting of 2 cc Celestone Soluspan (6mg/ml) and 2 cc of 1% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions.
Study: NCT01447498

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening for risk factors for ulcer bleeding
Description: Following PCI the patients fill out a questionnaire to assess the risk factors for ulcer bleeding.We randomise between:~1. screening and risk assessment~2. control group~All screened patients, who fulfil the criteria for having a moderate to high risk of ulcer bleeding will be sent written information about risk factors and the purpose of the PPI prophylaxis. They will be recommended PPI prophylaxis (Pantoprazole), as long as they are being treated with low-dose aspirin and clopidogrel.~Patients in the screening group, who are already on PPI treatment is recommended to change to Pantoprazole.~Definition of risk of ulcer bleeding: The table below will be used for screening. Patients scoring ≥ 2 points will receive PPI prophylaxis.~points: Age: \< 60: 0; 60-69: 1; 70-79: 2; \>=80: 3 ___ Dyspepsia: 1 ___ Uncomplicated ulcer: 2 ___ Complicated ulcer 3 ___ NSAID 2 ___ Steroids 2 ___ SSRI 2 ___ Anticoagulant Tx 2 ___